A New Approach to Inotropic Therapy in the Treatment of Heart Failure: Cardiac Myosin Activators in Treatment of HF

Cardiology in Review

Volumn 21, Issue 3, 2013, Pages 155-159

  Garg, Vinisha ^a   Frishman, William H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

cardiac myosin activator; CK 1827452; heart failure; inotrope; omecamtiv mecarbil; systolic ejection time

Indexed keywords

CALCIUM; CARDIAC MYOSIN; INOTROPIC AGENT; MYOSIN; OMECAMTIV MECARBIL; PLACEBO;

DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; HEART FAILURE; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE EJECTION TIME; HEART VENTRICLE FILLING; HEART VENTRICLE HYPERTROPHY; HUMAN; MAXIMUM TOLERATED DOSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DOMAIN; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ANIMALS; CARDIAC MYOSINS; CARDIOTONIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DISEASE MODELS, ANIMAL; DOGS; DRUG EVALUATION; HEART FAILURE, SYSTOLIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; RATS, SPRAGUE-DAWLEY; UREA;

EID: 84876408911     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318275889c     Document Type: Review

References (25)

1. Roger VL, Go AS, Lloyd-Jones DM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:188-197.
2. Braunwald E: Heart failure. J Am Coll Cardiol Heart Failure. 2013;1:1-120.
3. McMurray JJ. Clinical practice. Systolic heart failure. N Engl J Med. 2010;362:228-238.
4. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977-2016.
5. Teerlink JR. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev. 2009;14:289-298.
6. Asai K, Uechi M, Sato N, et al. Lack of desensitization and enhanced efficiency of calcium channel promoter in conscious dogs with heart failure. Am J Physiol. 1998;275(6 pt 2):H2219-H2226.
7. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211. (Pubitemid 12079105)
8. Shen YT, Malik FI, Zhao X, et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail. 2010;3:522-527.
9. Malik FI, Morgan BP. Cardiac myosin activation part 1: from concept to clinic. J Mol Cell Cardiol. 2011;51:454-461.
10. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation. 2006;113:305-315.
11. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998;339:1810-1816. (Pubitemid 29005785)
12. Felker GM, Benza RL, Chandler AB, et al.; OPTIME-CHF Investigators. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41:997-1003. (Pubitemid 36315544)
13. Cuffe MS, Califf RM, Adams KF Jr, et al.; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-1547. (Pubitemid 34269999)
14. Metra M, Bettari L, Carubelli V, et al. Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents. Drugs. 2011;71:515-525.
15. Dec GW. Digoxin remains useful in the management of chronic heart failure. Med Clin North Am. 2003;87:317-337. (Pubitemid 36384085)
16. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
17. LeJemtel TH, Klapholz M, Frishman WH. Inotropic agents. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 3rd ed. Minneapolis, MN: Cardiotext Inc.; 2011:189-203.
18. Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011;331:1439-1443.
19. Holmes KC, Angert I, Kull FJ, et al. Electron cryo-microscopy shows how strong binding of myosin to actin releases nucleotide. Nature. 2003;425:423-427. (Pubitemid 37187274)
20. Banfor PN, Preusser LC, Campbell TJ, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol. 2008;294:H238-H248.
21. Teerlink JR, Clarke CP, Saikali KG, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011;378:667-675.
22. Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011;378:676-683.
23. Greenberg BH, Chou W, Escandon R, et al. Phase II safety study evaluating the novel cardiac myosin activator, CK-1827452, in patients with ischemic cardiomyopathy and angina. J Card Fail. 2009;15(suppl 6):S67.
24. Study to Evaluate the Safety and Efficacy of Intravenous Infusion Treatment with Omecamtiv Mecarbil in Subjects with Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure. Available at: www.clinicaltrials.gov identifier: NCT01300013. Accessed February 21, 2013.
25. Jerling M, Chew T, Escandon RD, et al. Oral bioavailability of the selective cardiac myosin activator CK-1827452: chronic oral inotropic therapy for heart failure? J Card Fail. 2007;13(6 suppl 2):S148.